Galena Biopharma (GALE) Presents Data from NeuVax Phase 1/2 in Breast Cancer
Tweet Send to a Friend
Galena Biopharma, Inc. (Nasdaq: GALE) presented data from the Phase 1/2 clinical trial of NeuVax™ (nelipepimut-S or E75) at the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
